Trexquant Investment LP Jounce Therapeutics, Inc. Transaction History

Trexquant Investment LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$2.8 - $7.67 $54,608 - $149,588	-19,503 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$6.01 - $8.54 $179,584 - $255,183	-29,881 Reduced 60.51%	19,503 $132,000
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $351,120 - $476,061	49,384 New	49,384 $412,000
Q3 2021 Nov 12, 2021	SELL	$5.04 - $8.73 $167,942 - $290,901	-33,322 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$6.58 - $10.66 $219,258 - $355,212	33,322 New	33,322 $227,000
Q1 2021 May 13, 2021	SELL	$6.73 - $13.87 $162,892 - $335,709	-24,204 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$6.37 - $10.33 $154,179 - $250,027	24,204 New	24,204 $169,000
Q1 2020 May 08, 2020	SELL	$2.91 - $8.7 $199,416 - $596,193	-68,528 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$2.81 - $9.21 $192,563 - $631,142	68,528 New	68,528 $598,000
Q4 2018 Feb 13, 2019	SELL	$2.69 - $6.71 $89,299 - $222,751	-33,197 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$6.5 - $8.37 $215,780 - $277,858	33,197 New	33,197 $216,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.